Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1010 • ACR Convergence 2022
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos¹, Pedro Machado², Lars Bauer³, Bengt Hoepken³, Mindy Kim⁴, Thomas Kumke³, Rachel Tham⁵ and Martin Rudwaleit⁶, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University College London, London, United Kingdom, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
Abstract Number: 1891 • ACR Convergence 2022
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
Walter P Maksymowych¹, Louis Bessette², Robert G Lambert³, Amanda Carapellucci⁴ and Tom Appleton⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴CARE Arthritis LTD, Edmonton, AB, Canada, ⁵The University of Western Ontario, London, ON, Canada
Background/Purpose: Recent RCTs demonstrated that TNFα inhibition has no effect on pain and MRI-detected synovitis or bone marrow lesions in patients with erosive hand OA.…
Abstract Number: 0430 • ACR Convergence 2022
The Course of Bone Mineral Density During 8 Years of Treatment with TNF-α Inhibitors in Patients with Ankylosing Spondylitis
Mark Siderius¹, Anneke Spoorenberg², Freke Wink³ and Suzanne Arends², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Medical Center Leeuwarden, Leeuwarden, Netherlands
Background/Purpose: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis…
Abstract Number: 1137 • ACR Convergence 2022
MHC Class I Polypeptide-Related Sequence a Variant Predicts Real-World Response to Anti-TNF Therapy
Kristin Wipfler¹, Joshua Baker² and Kaleb Michaud³, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: MHC class I polypeptide-related sequence A (MICA) is a protein involved in the activation of NK and T cells. Variants within the MICA gene…
Abstract Number: 1966 • ACR Convergence 2022
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Eva van Geel¹, Bafrin Abdulmajid¹, Annelies Blanken² and Michael Nurmohamed³, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
Abstract Number: 0543 • ACR Convergence 2022
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Martin Rudwaleit¹, Filip Van den bosch², Helena Marzo-Ortega³, Victoria Navarro-Compán⁴, Rachel Tham⁵, Thomas Kumke⁶, Lars Bauer⁶, Mindy Kim⁷ and Lianne Gensler⁸, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ²Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ³Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Smyrna, GA, ⁸Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: In clinical trials of axial spondyloarthritis (axSpA), composite measures such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response criteria, Assessment of Spondyloarthritis international…
Abstract Number: 1210 • ACR Convergence 2022
Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
Namrata Singh¹, Alexander Peterson², Aaron Baraff², Ajay Gopal³, Nicholas Smith⁴, Jennifer Barton⁵, Jeffrey Curtis⁶ and Noel Weiss³, ¹University of Washington, Bellevue, WA, ²VA Puget Sound, SEATTLE, WA, ³University of Washington, Seattle, WA, ⁴VA Puget Sound/University of Washington, Seattle, WA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) are associated with lymphoma development [1]. Whether the decrease…
Abstract Number: 1977 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Predicts Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNFα Therapy
Jonathan Graf¹, Martin Jacobs², Debbie Gladd-Foley³, Yelliann Ruiz-Irizarry⁴, Alan Kivitz⁵, Melvin Churchill⁶, Arash Kardan⁷, Mara Leach⁸, David Ralph⁸, Nicole Korczak⁸, Addison Hasselbach⁸, Bonnie Abbruzzese⁸, Rachael Hershey⁸, Beth Potter⁸, Jessica Fitzpatrick⁸, Aaron Thornton⁸, Michael Blue⁸ and Michael Rosol⁸, ¹Ucsf, San Francisco, CA, ²Kettering Network Radiologists, Kettering, OH, ³Premier Rheumatology of Oklahoma, Tulsa, OK, ⁴Jackson Health System, Innovation Medical Research Center, Palmetto Bay, FL, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Arthritis Center of Nebraska, Bryan Health, Lincoln, NE, ⁷Baylor College of Medicine, Department of Radiology, Houston, TX, ⁸Navidea Biopharmaceuticals, Dublin, OH
Background/Purpose: Effective and expeditious control of rheumatoid arthritis (RA) disease activity using a treat-to-target (T2T) strategy is crucial to prevent long term damage and disability.…
Abstract Number: 0546 • ACR Convergence 2022
COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial
Fabian Proft¹, Bukrhard Muche², valeria Rios-Rodriguez³, Murat Torgutalp⁴, Mikhail Protopopov⁵, Joachim Listing⁶, Maryna Verba⁷, Jan Brandt-Juergens⁸, Uta Kiltz⁹, Maren Sieburg¹⁰, Swen Jacki¹¹, Joachim Sieper⁴ and Denis Poddubnyy¹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany, ⁷Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁸Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Germany, ¹⁰Rheumatologische Facharztpraxis, Magdeburg, Germany, ¹¹Rheumatologische Schwerpunktpraxis, Tübingen, Germany
Background/Purpose: There is some evidence that NSAIDs, in particular celecoxib (CEL), might possess not only symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS),…
Abstract Number: 1395 • ACR Convergence 2022
Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao-Fan Fang¹ and Lai-Chu See², ¹Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan, Taiwan
Background/Purpose: Since 2010, biological disease-modifying antirheumatic drugs (bDMARDs) have been the dominant mode of treatment for rheumatoid arthritis (RA). However, the safety of DMARDs, such…
Abstract Number: 2121 • ACR Convergence 2022
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Laura Pina Vegas¹, Emilie sbidian² and Pascal Claudepierre³, ¹Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ²Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³Paris Est Creteil University, Creteil, France
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…
Abstract Number: 0547 • ACR Convergence 2022
Profiling of Systemic Immune Responses in Axial Spondyloarthritis Patients Reveals Strikingly Distinct Cellular and Molecular Mechanisms of Action of IL-17A Inhibitors and TNF-Blockers
Nicolas Rosine¹, Surya Koturan¹, Vincent Guillemot², Claire Leloup¹, Fanni Veress¹, Tharshana Stephen¹, Hanan Yahia-Cherbal¹, Jérémie SELLAM³, Francis Berenbaum⁴, Natalia Pietrosemoli¹, Elisabetta Bianchi¹, Corinne MIceli⁵ and Lars Rogge¹, ¹Institut Pasteur, Paris, France, ²Institut Pasteur, Paris, Ile-de-France, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁴Sorbonne University - Saint-Antoine hospital, Paris, France, ⁵APHP, Paris, France
Background/Purpose: IL-17A inhibitors (IL-17i) and TNF-inhibitors (TNFi) are currently the only biologic drugs available to treat axial spondyloarthritis (axSpA). While several studies have provided mechanistic…
Abstract Number: 1401 • ACR Convergence 2022
Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
George A Karpouzas¹, Zoltan Szekanecz², Eva Baecklund³, Ted Mikuls⁴, Deepak L Bhatt⁵, Harry Shi⁶, Cunshan Wang⁷, Gosford A Sawyerr⁸, Yan Chen⁶, Sujatha Menon⁷, Carol A Connell⁷, Steven R Ytterberg⁹ and Mahta Mortezavi⁸, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Pfizer, Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, New York, NY, ⁹Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Uncontrolled RA activity and acute disease flares are associated with higher risk of adverse outcomes, such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy,…
Abstract Number: 2137 • ACR Convergence 2022
Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis
Lihi Eder¹, Laura Coates², Peter Nash³, Uta Kiltz⁴, Ennio Lubrano⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁷ and Alexis Ogdie⁸, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie, Inc., North Chicago, IL, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Evidence suggests that response to treatment in PsA may vary with patient (pt) characteristics, such as sex.1 This post hoc analysis of the Phase…
Abstract Number: 0582 • ACR Convergence 2022
Development of Novel Glucocorticoid as Immunology Antibody-Drug Conjugate Payload for the Treatment of Autoimmune and Inflammatory Diseases
Xiaojuan Chai¹, Yayuan Fu¹, Lifeng Liu¹, Yuxi Yan¹, Quan Zhao¹, Xiaoqing Liu², Yixin Zou¹, Jing Dai¹, Feng Tang¹, Zhuoxiao Cao¹ and Renhong Tang¹, ¹Simcere Pharmaceutical Group, Shanghai, China, ²Simcere Pharmaceutical Group, Nanjing, China
Background/Purpose: Glucocorticoids (GCs) are widely used to treat a variety of autoimmune and inflammatory diseases like rheumatoid arthritis, inflammatory bowel disease, and asthma. The anti-inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].